Red Flags Detected
- Related Party Transaction (new) — The company sold its wholly-owned subsidiary to its own co-CEO and chairman in a related party transaction with unclear economic valuation.
- Departure Of Ceo (new) — Co-CEO Milton Chen resigned effective May 31, 2026, concurrent with acquiring subsidiary VSee Lab, though the company states the departure was amicable.
VSee Health sells subsidiary to departing co-CEO Chen for 2.87M shares
Filed June 5, 2026 · Period ending May 31, 2026 · ~1 min read
Key Changes
-
high
Company sold wholly-owned subsidiary VSee Lab to co-CEO Milton Chen on May 31, 2026, in exchange for 2.87 million shares of common stock he owned, effectively executing a stock buyback tied to a divestiture.
Item 1.01 verify on EDGAR → -
high
Milton Chen resigned as co-CEO and board chairman effective May 31, 2026, concurrent with the VSee Lab acquisition. Dr. Imoigele Aisiku, the other co-CEO, was appointed sole CEO and chairman.
Item 5.02 verify on EDGAR → -
medium
Chen assumed responsibility for VSee Lab's unpaid debts and liabilities post-closing, while the company retains liability for pre-closing taxes and obligations.
Item 1.01 verify on EDGAR →
2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade VSEEW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 4:36 AM